Organon (NYSE: OGN), a global healthcare company with a mission to improve the health of women throughout their lives, and Dermavant Sciences Ltd. announce that they have entered into a definitive agreement, under which Organon will acquire Dermavant, a Roivant (NASDAQ: ROIV) company dedicated to developing and commercializing innovative therapeutics in immuno-dermatology. Dermavant’s novel product, VTAMA® (tapinarof) cream, 1%, for the topical treatment of mild, moderate, and severe plaque psoriasis in adults, was approved by the U.S. Food and Drug Administration (FDA) in May 2022.
Read the full article: Organon to Acquire Dermavant //
Source: https://www.businesswire.com/news/home/20240918672903/en/Organon-to-Acquire-Dermavant-including-its-Innovative-Dermatologic-Therapy-VTAMA%C2%AE-tapinarof-Cream-1